Table 2: The genotypic frequencies of twelve mutations in ten cardiovascular disease genes in coronary artery patients and healthy control groups.
|
Coronary artery patients |
Healthy controls |
|
||||||
Gene mutations |
n |
Homozygote Wild type |
Heterozygote |
Homozygote |
N |
Homozygote Wild type |
Heterozygote |
Homozygote Mutant |
p value* |
(Total) |
n (%) |
n (%) |
Mutant |
(Total) |
n (%) |
n (%) |
n (%) |
||
|
|
|
n (%) |
|
|
|
|
||
Factor V Leiden |
27 |
26 (96.3) |
1 (3.7) |
0 |
8 |
8 (100) |
0 |
0 |
0.581 |
Factor V (H1299R) |
24 |
20 (83.3) |
4 (16.7) |
0 |
7 |
6 (85.7) |
1 (14.3) |
0 |
0.88 |
Prothrombin (G20210A) |
30 |
29 (96.7) |
1 (3.3) |
0 |
8 |
7 (87.5) |
1 (12.5) |
0 |
0.302 |
Factor XIII (V34L) |
7 |
6 (85.7) |
1 (14.3) |
0 |
4 |
4 (100) |
0 |
0 |
0.428 |
β-Fibrinojen (-455G > A) |
18 |
12 (66.7) |
6 (33.3) |
0 |
6 |
5 (83.3) |
1 (16.7) |
0 |
0.437 |
MTHFR (C677T) |
15 |
9 (60) |
3 (20) |
3 (20) |
7 |
4 (57.1) |
2 (28.6) |
1 (14.3) |
0.884 |
MTHFR (A1298C) |
48 |
10 (20.8) |
37 (77.1) |
1 (2.1) |
39 |
2 (5.1) |
37 (94.9) |
0 |
0.008 |
APOB (R3500Q) |
13 |
13 (100) |
0 |
0 |
4 |
4 (100) |
0 |
0 |
Not estimated |
PAI-1 (4G/5G) |
19 |
5G/5G |
5G/4G |
4G/4G |
7 |
5G/5G |
5G/4G |
4G/4G |
|
8 (42.1) |
8 (42.1) |
3 (15.8) |
4 (57.1) |
1 (14.3) |
2 (28.6) |
0.401 |
|||
HPA-1 (1a/1b) |
15 |
1a/1a |
1a/1b |
1b/1b |
5 |
1a/1a |
1a/1b |
1b/1b |
|
10 (66.7) |
5 (33.3) |
0 |
5 (100) |
0 |
0 |
0.136 |
|||
ACE (intron 16 I/D) |
43 |
DEL |
DEL/INS |
INS |
25 |
DEL |
DEL/INS |
INS |
|
2 (4.7) |
30 (69.8) |
11 (25.6) |
2 (8) |
17 (68) |
6 (24) |
0.85 |
|||
APOE (E2, E3. E4) |
36 |
E2/E3 |
E3/E3 |
E3/E4 |
11 |
E2/E3 |
E3/E3 |
E3/E4 |
|
4 (4.7) |
30 (69.8) |
2 (5.6) |
0 |
10 (90.9) |
1 (9.1) |
0.486 |
The statistically significant results are written in bold. ACE: Angiotensin converting enzyme; APOB: Apolipoprotein B; APOE: Apolipoprotein E; HPA-1: Human platelet antigen 1; MTHFR: Methylene tetrahydrofolate reductase; PAI-1: Plasminogen activator inhibitor-1; *Evaluated by Pearson’s Chi squared test.